Advertisement

Volume 129, Issue 6

WASHINGTON, February 9, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota
Josefsdottir and colleagues demonstrate that antibiotic-induced bone marrow suppression is mediated through contraction of the gut microbiome that can be partially rescued by fecal microbiota transfer.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML
Despite chemotherapy-induced leukopenia, acute myeloid leukemia (AML) patients do not appear to be predisposed to viral infections. Alsuliman et al explain this observation by describing a subset of virus-specific CD161+ T cells that express MDR1 and are resistant to AML chemotherapy.

Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA
and
Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function
Two papers in this week’s issue use phenotypic and genotypic data in large databases to establish that sickle cell trait is not a risk factor for cardiovascular events. This should help lay to rest the ongoing controversy about the impact of sickle cell trait on cardiac fitness.

Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease
Martin and colleagues use genomics to characterize the divergent impact of minor histocompatibility mismatching on graft-versus-host disease (GVHD) in matched sibling transplants and unrelated donor transplant-related GVHD.

Introduction to a review series on myeloproliferative neoplasms
This comprehensive review series on myeloproliferative neoplasms provides an update on the rapidly evolving understanding of the genetic underpinnings of these diseases and its impact on improving therapy.

The articles in this review series, "Myeloproliferative Neoplasms," include the following:

This week's complete table of contents

Why Submit to Blood?

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.